Use of this injectable hydrogel nanocarrier to deliver OVA-encoding mRNA generated ovalbumin and adjuvant-laden nanovaccines and markedly increased the number of antigen-specific CD8 T cells, thereby inhibiting tumor growth 166. This evidence concerns the gene CD8A and neoplasm.